<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.soap.ontology.v1.OntologyDrugSummaryOutput xmlns:ns2="local" id="13340" name="everolimus"><HDS>Launched</HDS><RegulatoryDesignations><RegulatoryDesignation id="5">Accelerated Approval</RegulatoryDesignation><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><RegulatoryDesignation id="19">Special Review Project</RegulatoryDesignation></RegulatoryDesignations><Actions><Action id="76090" type="primary">mTOR complex 1 inhibitor</Action><Action id="10240" type="primary">mTOR inhibitor</Action><Action id="1545" type="secondary">Anticancer</Action><Action id="396" type="secondary">Immunosuppressant</Action><Action id="61" type="secondary">Angiogenesis inhibitor</Action><Action id="62255" type="secondary">Anticancer protein kinase inhibitor</Action><Action id="70" type="secondary">Anticonvulsant agent</Action><Action id="991" type="secondary">Antiviral</Action></Actions><Indications><Indication id="1011" type="primary">Esophagus tumor</Indication><Indication id="1108" type="primary">Glioma</Indication><Indication id="1128" type="primary">Neuroendocrine tumor</Indication><Indication id="1134" type="primary">Thyroid tumor</Indication><Indication id="1262" type="primary">Non-small-cell lung cancer</Indication><Indication id="1264" type="primary">Macroglobulinemia</Indication><Indication id="1510" type="primary">Pancreatic endocrine tumor</Indication><Indication id="1705" type="primary">Endometrioid carcinoma</Indication><Indication id="1728" type="primary">Acute lymphoblastic leukemia</Indication><Indication id="1766" type="primary">Renal cell carcinoma</Indication><Indication id="2380" type="primary">Bladder cancer</Indication><Indication id="2453" type="primary">Astrocytoma</Indication><Indication id="2789" type="primary">Angiomyolipoma</Indication><Indication id="2987" type="primary">Heart transplant rejection</Indication><Indication id="2988" type="primary">Liver transplant rejection</Indication><Indication id="2989" type="primary">Kidney transplant rejection</Indication><Indication id="3070" type="primary">Multiple hamartoma sydrome</Indication><Indication id="3240" type="primary">Medullary thyroid cancer</Indication><Indication id="3439" type="primary">Partial seizure</Indication><Indication id="3657" type="primary">Metastatic breast cancer</Indication><Indication id="4250" type="primary">Metastatic renal cell carcinoma</Indication><Indication id="49" type="primary">Breast tumor</Indication><Indication id="515" type="primary">Transplant rejection</Indication><Indication id="623" type="primary">Head and neck tumor</Indication><Indication id="989" type="primary">Colorectal tumor</Indication><Indication id="1123" type="secondary">Herpesvirus type 8 infection</Indication><Indication id="119" type="secondary">Epilepsy</Indication><Indication id="1226" type="secondary">Age related macular degeneration</Indication><Indication id="1240" type="secondary">Mesothelioma</Indication><Indication id="1261" type="secondary">Small-cell lung cancer</Indication><Indication id="127" type="secondary">Stomach tumor</Indication><Indication id="161" type="secondary">Hodgkins disease</Indication><Indication id="1614" type="secondary">Sturge-Weber syndrome</Indication><Indication id="1731" type="secondary">Acute myelogenous leukemia</Indication><Indication id="1744" type="secondary">Mantle cell lymphoma</Indication><Indication id="1749" type="secondary">Diffuse large B-cell lymphoma</Indication><Indication id="1754" type="secondary">Cutaneous T-cell lymphoma</Indication><Indication id="1767" type="secondary">Hepatocellular carcinoma</Indication><Indication id="1828" type="secondary">Multiple myeloma</Indication><Indication id="189" type="secondary">Inflammatory bowel disease</Indication><Indication id="194" type="secondary">Sarcoma</Indication><Indication id="203" type="secondary">Lymphoma</Indication><Indication id="205" type="secondary">Melanoma</Indication><Indication id="2054" type="secondary">Hematological neoplasm</Indication><Indication id="2243" type="secondary">Fallopian tube cancer</Indication><Indication id="2300" type="secondary">Autosomal dominant polycystic kidney disease</Indication><Indication id="249" type="secondary">Pancreas tumor</Indication><Indication id="2802" type="secondary">Meningioma</Indication><Indication id="291" type="secondary">Rheumatoid arthritis</Indication><Indication id="3083" type="secondary">Peritoneal tumor</Indication><Indication id="3129" type="secondary">Tuberous sclerosis</Indication><Indication id="3141" type="secondary">Lung transplant rejection</Indication><Indication id="319" type="secondary">Non-Hodgkin lymphoma</Indication><Indication id="3205" type="secondary">Gastrointestinal stromal tumor</Indication><Indication id="3246" type="secondary">Hormone refractory prostate cancer</Indication><Indication id="341" type="secondary">Uveitis</Indication><Indication id="3521" type="secondary">Neurofibromatosis type I</Indication><Indication id="3713" type="secondary">Advanced solid tumor</Indication><Indication id="3788" type="secondary">Uveal melanoma</Indication><Indication id="3907" type="secondary">Renal insufficiency</Indication><Indication id="427" type="secondary">Uterine cervix tumor</Indication><Indication id="609" type="secondary">Genetic disorder</Indication><Indication id="708" type="secondary">Pulmonary fibrosis</Indication><Indication id="725" type="secondary">Solid tumor</Indication><Indication id="799" type="secondary">Ovary tumor</Indication></Indications><Entities><Entity>Chemical</Entity></Entities><OriginatorCompany id="23137">Novartis AG</OriginatorCompany></ns2:com.thomsonreuters.ls.service.contract.soap.ontology.v1.OntologyDrugSummaryOutput>